The potential of p16 as a pharmacodynamic (PD) biomarker for DNMT inhibitors has also been demonstrated, with treatment-induced increases in p16 expression observed in patient tumors from a phase 1 trial of decitabine in lung and esophageal cancers [7]. This evidence concerns the gene CDKN2A and esophageal cancer.